Radiotherapy & Oncology
Volume 94, Issue 2 , Pages 125-128 , February 2010

Vorsprung durch Technik: Evolution, implementation, QA and safety of new technology in radiotherapy

References 

  1. 10th Biennial ESTRO conference on physics and technology for clinical radiotherapy, Aug 30–Sep 3, 2009. Radiother Oncol 2009;92:(Suppl. 1).
  2. Nystrom H, Thwaites DI. Physics and high-technology advances in radiotherapy: are they still worth it?. Radiother Oncol. 2008;86:1–3
  3. Rodemann HP. Molecular radiation biology: perspectives for radiation oncology. Radiother Oncol. 2009;92:293–298
  4. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother Oncol. 2009;9:85–94
  5. Lavrenkov K, Singh S, Christian JA, et al. Effective avoidance of a functional spect-perfused lung using intensity modulated radiotherapy (IMRT) for non-small cell lung cancer (NSCLC): an update of a planning study. Radiother Oncol. 2009;91:349–352
  6. Rosewall T, Kong V, Vesprini D, et al. Prostate delineation using CT and MRI for radiotherapy patients with bilateral hip prostheses. Radiother Oncol. 2009;90:325–330
  7. Vilarino-Varela MJ, Taylor A, Rockall AG, et al. A verification study of proposed pelvic lymph node localisation guidelines using nanoparticle-enhanced magnetic resonance imaging. Radiother Oncol. 2008;89:92–96
  8. van Loon J, Offermann C, Bosmans G, et al. 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. Radiother Oncol. 2008;87:49–54
  9. Schinagl DA, Hoffmann AL, Vogel WV, et al. Can FDG-PET assist in radiotherapy target volume definition of metastatic lymph nodes in head-and-neck cancer?. Radiother Oncol. 2009;91:95–100
  10. van Baardwijk A, Bosmans G, van Suylen RJ, et al. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol. 2008;87:55–58
  11. Aerts HJ, van Baardwijk AA, Petit SF, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol. 2009;91:386–392
  12. Abramyuk A, Tokalov S, Zophel K, et al. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?. Radiother Oncol. 2009;91:399–404
  13. Fenoglietto P, Laliberte B, Allaw A, et al. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk. Radiother Oncol. 2008;88:77–87
  14. Fenkell L, Kaminsky I, Breen S, et al. Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. Radiother Oncol. 2008;89:287–291
  15. St-Hilaire J, Sevigny C, Beaulieu F, et al. Dose escalation in the radiotherapy of non-small-cell lung cancer with aperture-based intensity modulation and photon beam energy optimization for non-preselected patients. Radiother Oncol. 2009;91:342–348
  16. Yaparpalvi R, Hong L, Mah D, et al. ICRU reference dose in an era of intensity-modulated radiation therapy clinical trials: correlation with planning target volume mean dose and suitability for intensity-modulated radiation therapy dose prescription. Radiother Oncol. 2008;89:347–352
  17. Moon SH, Shin KH, Kim TH, et al. Dosimetric comparison of four different external beam partial breast irradiation techniques: three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, helical tomotherapy, and proton beam therapy. Radiother Oncol. 2009;90:66–73
  18. Lee TF, Fang FM, Chao PJ, et al. Dosimetric comparisons of helical tomotherapy and step-and-shoot intensity-modulated radiotherapy in nasopharyngeal carcinoma. Radiother Oncol. 2008;89:89–96
  19. Sterzing F, Sroka-Perez G, Schubert K, et al. Evaluating target coverage and normal tissue sparing in the adjuvant radiotherapy of malignant pleural mesothelioma: helical tomotherapy compared with step-shoot IMRT. Radiother Oncol. 2008;86:251–257
  20. Caudrelier JM, Morgan SC, Montgomery L, et al. Helical tomotherapy for locoregional irradiation including the internal mammary chain in left-sided breast cancer: dosimetric evaluation. Radiother Oncol. 2009;90:99–105
  21. Cattaneo GM, Dell’oca I, Broggi S, et al. Treatment planning comparison between conformal radiotherapy and helical tomotherapy in the case of locally advanced-stage NSCLC. Radiother Oncol. 2008;88:310–318
  22. Iori M, Cattaneo GM, Cagni E, et al. Dose-volume and biological-model based comparison between helical tomotherapy and (inverse-planned) IMAT for prostate tumours. Radiother Oncol. 2008;88:34–45
  23. Cozzi L, Dinshaw KA, Shrivastava SK, et al. A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy. Radiother Oncol. 2008;89:180–191
  24. Fogliata A, Clivio A, Nicolini G, et al. Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques. Radiother Oncol. 2008;89:254–262
  25. Verbakel WF, Senan S, Cuijpers JP, et al. Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs. Radiother Oncol. 2009;93:122–124
  26. Clivio A, Fogliata A, Franzetti-Pellanda A, et al. Volumetric-modulated arc radiotherapy for carcinomas of the anal canal: a treatment planning comparison with fixed field IMRT. Radiother Oncol. 2009;92:118–124
  27. Guckenberger M, Richter A, Krieger T, et al. Is a single arc sufficient in volumetric-modulated arc therapy (VMAT) for complex-shaped target volumes?. Radiother Oncol. 2009;93:259–265
  28. Wolff D, Stieler F, Welzel G, et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol. 2009;93:226–233
  29. Wagner D, Christiansen H, Wolff H, et al. Radiotherapy of malignant gliomas: comparison of volumetric single arc technique (RapidArc), dynamic intensity-modulated technique and 3D conformal technique. Radiother Oncol. 2009;93:593–596
  30. Thorwarth D, Soukup M, Alber M. Dose painting with IMPT helical tomotherapy and IMXT: a dosimetric comparison. Radiother Oncol. 2008;86:30–34
  31. Georg D, Hillbrand M, Stock M, et al. Can protons improve SBRT for lung lesions? Dosimetric considerations. Radiother Oncol. 2008;88:368–375
  32. Widesott L, Amichetti M, Schwarz M. Proton therapy in lung cancer: clinical outcomes and technical issues. A systematic review. Radiother Oncol. 2008;86:154–164
  33. Hillbrand M, Georg D, Gadner H, et al. Abdominal cancer during early childhood: a dosimetric comparison of proton beams to standard and advanced photon radiotherapy. Radiother Oncol. 2008;89:141–149
  34. Verellen D, De Ridder M, Storme GA. (Short) History of image-guided radiotherapy. Radiother Oncol. 2008;86:4–13
  35. Korreman S, Rasch C, McNair H, et al. The European Society of Therapeutic Radiology and Oncology-European Institute of Radiotherapy (ESTRO-EIR) report on 3D CT-based in-room image guidance systems: A practical and technical review and guide. Radiother Oncol. 2010;94:129–144
  36. Lagendijk JJ, Raaymakers BW, Raaijmakers AJ, et al. MRI/linac integration. Radiother Oncol. 2008;86:25–29
  37. Stutzel J, Oelfke U, Nill S. A quantitative image quality comparison of four different image guided radiotherapy devices. Radiother Oncol. 2008;86:20–24
  38. Calcerrada Diaz-Santos N, Blasco Amaro JA, Cardiel GA, et al. The safety and efficacy of robotic image-guided radiosurgery system treatment for intra- and extracranial lesions: a systematic review of the literature. Radiother Oncol. 2008;89:245–253
  39. Guckenberger M, Krieger T, Richter A, et al. Potential of image-guidance, gating and real-time tracking to improve accuracy in pulmonary stereotactic body radiotherapy. Radiother Oncol. 2009;9:288–295
  40. Castadot P, Lee JA, Parraga A, et al. Comparison of 12 deformable registration strategies in adaptive radiation therapy for the treatment of head and neck tumors. Radiother Oncol. 2008;89:1–12
  41. Schulze D, Liang J, Yan D, et al. Comparison of various online IGRT strategies: the benefits of online treatment plan re-optimization. Radiother Oncol. 2009;90:367–376
  42. van Haaren PM, Bel A, Hofman P, et al. Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients. Radiother Oncol. 2009;90:291–298
  43. Zeng GG, Breen SL, Bayley A, et al. A method to analyze the cord geometrical uncertainties during head and neck radiation therapy using cone beam CT. Radiother Oncol. 2009;90:228–230
  44. van de Bunt L, Jurgenliemk-Schulz IM, de Kort GA, et al. Motion and deformation of the target volumes during IMRT for cervical cancer: what margins do we need?. Radiother Oncol. 2008;88:233–240
  45. Wang L, Hayes S, Paskalev K, et al. Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: evaluation of the impact on daily dose coverage. Radiother Oncol. 2009;91:314–324
  46. Ehler ED, Tome WA. Lung 4D-IMRT treatment planning: an evaluation of three methods applied to four-dimensional data sets. Radiother Oncol. 2008;88:319–325
  47. Admiraal MA, Schuring D, Hurkmans CW. Dose calculations accounting for breathing motion in stereotactic lung radiotherapy based on 4D-CT and the internal target volume. Radiother Oncol. 2008;86:55–60
  48. McDermott LN, Wendling M, Nijkamp J, et al. 3D in vivo dose verification of entire hypo-fractionated IMRT treatments using an EPID and cone-beam CT. Radiother Oncol. 2008;86:35–42
  49. Pawlicki T, Yoo S, Court LE, et al. Moving from IMRT QA measurements toward independent computer calculations using control charts. Radiother Oncol. 2008;89:330–337
  50. Wagner D, Anton M, Vorwerk H, et al. In vivo alanine/electron spin resonance (ESR) dosimetry in radiotherapy of prostate cancer: a feasibility study. Radiother Oncol. 2008;88:140–147
  51. Reynders T, Tournel K, De Coninck P, et al. Dosimetric assessment of static and helical TomoTherapy in the clinical implementation of breast cancer treatments. Radiother Oncol. 2009;93:71–79
  52. Potter R. Image-guided brachytherapy sets benchmarks in advanced radiotherapy. Radiother Oncol. 2009;91:141–146
  53. Sims R, Isambert A, Gregoire V, et al. A pre-clinical assessment of an atlas-based automatic segmentation tool for the head and neck. Radiother Oncol. 2009;93:474–478
  54. Morgan AM, Knoos T, McNee SG, et al. Clinical implications of the implementation of advanced treatment planning algorithms for thoracic treatments. Radiother Oncol. 2008;86:48–54
  55. Huyskens DP, Maingon P, Vanuytsel L, et al. A qualitative and a quantitative analysis of an auto-segmentation module for prostate cancer. Radiother Oncol. 2009;90:337–345
  56. Pooler AM, Mayles HM, Naismith OF, et al. Evaluation of margining algorithms in commercial treatment planning systems. Radiother Oncol. 2008;86:43–47
  57. Fotina I, Winkler P, Kunzler T, et al. Advanced kernel methods vs. Monte Carlo-based dose calculation for high energy photon beams. Radiother Oncol. 2009;93:645–653
  58. Widesott L, Amichetti M, Schwarz M. Proton therapy in lung cancer: clinical outcomes and technical issues. A systematic review. Radiother Oncol. 2008;86154–86164
  59. Ghadjar P, Matzinger O, Isaak B, et al. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Radiother Oncol. 2009;91:237–242
  60. Rose J, Rodrigues G, Yaremko B, et al. Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. Radiother Oncol. 2009;91:282–287
  61. Fonteyne V, Villeirs G, Lumen N, et al. Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. Radiother Oncol. 2009;92:42–47
  62. Baumann M, Zips D, Appold S. Radiotherapy of lung cancer: technology meets biology meets multidisciplinarity. Radiother Oncol. 2009;91:279–281
  63. AAPM task group 40 report, Comprehensive QA for radiation oncology. Med Phys 1994;21:518–618.
  64. Department of Health (UK). Quality assurance in radiotherapy: a quality management system for radiotherapy. 1994 PL/CMO(94). London:DH.
  65. Thwaites D, Scalliet P, Leer JW, et al. Quality assurance in radiotherapy. European Society for Therapeutic Radiology and Oncology Advisory Report to the Commission of the European Union for the ‘Europe Against Cancer Programme’. Radiother Oncol. 1995;35:61–73
  66. Williamson JF, Dunscombe PB, Sharpe MB, et al. Quality assurance needs for modern image-based radiotherapy: recommendations from 2007 interorganizational symposium on ‘quality assurance of radiation therapy: challenges of advanced technology’. Int J Radiat Oncol Biol Phys. 2008;71(Suppl. 1):2–12
  67. IAEA. Comprehensive audits of radiotherapy practices: a tool for quality improvement. 2007, STI/PUB/1297. Vienna:IAEA. www.iaea.org.
  68. Palta JR, Liu C, Li JG. Current external beam radiation therapy quality assurance guidance. Does it meet the challenges of emerging image-guided technologies?. Int J Radiat Oncol Biol Phys. 2008;71(Suppl. 1):13–17
  69. Ekaette E, Lee RC, Cooke DL, et al. Probabilistic fault tree analysis of a radiation treatment system. Risk Anal. 2007;27:1395–1410
  70. Ford EC, Gaudette R, Myers L, et al. Evaluation of safety in a radiation oncology setting using failure mode and effects analysis. Int J Radiat Oncol Biol Phys. 2009;74:852–858
  71. Scorsetti M, Signori C, Lattuada P, et al. Applying failure mode effects and criticality analysis in radiotherapy: lessons learned and perspectives of enhancement. Radiother Oncol 2010; doi:10.1016/j.rodonc.2009.12.040.
  72. IPEM report 92. Balancing costs and benefits of checking in radiotherapy. 2006. York:IPEM. www.ipem.ac.uk.
  73. RCR,SCoR,IPEM,NPSA,BIR. Towards safer radiotherapy. 2008 London: the Royal College of Radiologists. www.rcr.ac.uk.
  74. Huq MS, Fraass BA, Dunscombe PB, et al. A method for evaluating quality assurance needs in radiation therapy. Int J Radiat Oncol Biol Phys. 2008;71(Suppl. 1):170–173
  75. Abdel-Wahab M, Rengan R, Curran B, et al. Integrating the healthcare enterprise in radiation oncology plug and play – the future of radiation oncology. Int J Radiat Oncol Biol Phys. 2010;76:333–336
  76. Ibbott GS, Followill DS, Molineau HA, et al. Challenges in credentialing institutions and participants in advanced technology multi-institutional clinical trials. Int J Radiat Oncol Biol Phys. 2008;71(Suppl. 1):71–75
  77. Johansson KA, Nilsson P, Zackrisson B, et al. The quality assurance process for the ARTSCAN head and neck study – a practical interactive approach for QA in 3DCRT and IMRT. Radiother Oncol. 2008;87:290–299
  78. Clark CH, Hansen VN, Chantler H, et al. Dosimetry audit for a multi-centre IMRT head and neck trial. Radiother Oncol. 2009;93:102–108
  79. Scalliet P. Risk, society and system failure. Radiother Oncol. 2006;80:275–281
  80. Shafiq J, Barton M, Noble D, et al. An international review of patient safety measures in radiotherapy practice. Radiother Oncol. 2009;92:15–21
  81. Fraass BA. Errors in radiotherapy: motivation for development of new radiotherapy quality assurance paradigms. Int J Radiat Oncol Biol Phys. 2008;71(Suppl. 1):162–165
  82. Radiation Oncology Safety Information System, available at www.clin.radfys.lu.se.
  83. Munro AJ. Hidden danger, obvious opportunity: error and risk in the management of cancer. Br J Radiol. 2007;80:955–966
  84. Norlund A. Costs of radiotherapy. Acta Oncol. 2003;42:411–415

PII: S0167-8140(10)00081-2

doi: 10.1016/j.radonc.2010.02.004

Radiotherapy & Oncology
Volume 94, Issue 2 , Pages 125-128 , February 2010

Article Tools